IKNA

Ikena Oncology, Inc. [IKNA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IKNA Stock Summary

Top 10 Correlated ETFs

IKNA


Top 10 Correlated Stocks

IKNA


In the News

10:36 29 Mar 2024 IKNA

Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

10:16 29 Mar 2024 IKNA

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

09:53 29 Mar 2024 IKNA

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

08:00 29 Mar 2024 IKNA

Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen's 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023.

10:41 29 Mar 2024 IKNA

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.47 per share a year ago.

03:50 29 Mar 2024 IKNA

Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?

Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

09:58 29 Mar 2024 IKNA

Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

11:30 29 Mar 2024 IKNA

Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:05 29 Mar 2024 IKNA

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, IK-175, will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which will be held in-person in Boston, MA and virtually on November 8-12, 2022.

07:00 29 Mar 2024 IKNA

Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.

IKNA Financial details

Company Rating
Sell
Market Cap
71.42M
Income
-66.87M
Revenue
9.16M
Book val./share
3.55
Cash/share
3.67
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.4
Forward P/E
-0.94
PEG
1.12
P/S
6.74
P/B
0.55
P/C
0.39
P/FCF
-1.24
Quick Ratio
10.22
Current Ratio
10.41
Debt / Equity
0.06
LT Debt / Equity
0.04
-
-
EPS (TTM)
-1.61
EPS next Y
-1.51
EPS next Q
-0.38
EPS this Y
-11.41%
EPS next Y
-6.21%
EPS next 5Y
-50.93%
EPS last 5Y
6.32%
Revenue last 5Y
-7.81%
Revenue Q/Q
-44.39%
EPS Q/Q
2.5%
-
-
-
-
SMA20
2.82%
SMA50
-21.08%
SMA100
-63.22%
Inst Own
67.07%
Inst Trans
0.78%
ROA
-28%
ROE
-41%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-492%
Profit Margin
-433%
Payout
-
Shs Outstand
48.26M
Shs Float
25.16M
-
-
-
-
Target Price
-
52W Range
1.02-7.64
52W High
-79.71%
52W Low
+42%
RSI
45.9
Rel Volume
0.39
Avg Volume
398.11K
Volume
155.35K
Perf Week
-5.33%
Perf Month
10.94%
Perf Quarter
-66.03%
Perf Half Y
-67.87%
-
-
-
-
Beta
0.324
-
-
Volatility
0.06%, 0.07%
Prev Close
2.16%
Price
1.42
Change
1.43%

IKNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.980.271.110.430.22
Net income per share
-1.2-1.28-1.22-1.84-1.63
Operating cash flow per share
3.43-1.09-2.15-2.05-1.91
Free cash flow per share
3.4-1.12-2.22-2.09-1.92
Cash per share
5.874.78.34.344.2
Book value per share
-4.39-2.927.434.064.07
Tangible book value per share
-4.39-2.927.434.064.07
Share holders equity per share
-4.39-2.927.434.064.07
Interest debt per share
5.825.960.250.220.26
Market cap
447.6M1.11B350.91M96.26M82.22M
Enterprise value
444.39M944.51M125.68M42.04M-26.94M
P/E ratio
-26.62-25.01-10.29-1.44-1.21
Price to sales ratio
32.55120.3811.336.168.98
POCF ratio
9.34-29.26-5.82-1.3-1.03
PFCF ratio
9.4-28.68-5.66-1.27-1.03
P/B Ratio
-7.28-10.951.690.650.48
PTB ratio
-7.28-10.951.690.650.48
EV to sales
32.31102.734.062.69-2.94
Enterprise value over EBITDA
-24.35-21.36-3.74-0.60.36
EV to operating cash flow
9.27-24.97-2.09-0.570.34
EV to free cash flow
9.33-24.47-2.03-0.560.34
Earnings yield
-0.04-0.04-0.1-0.69-0.83
Free cash flow yield
0.11-0.03-0.18-0.78-0.97
Debt to equity
-1.32-2.040.030.040.06
Debt to assets
0.951.220.030.030.06
Net debt to EBITDA
0.183.676.70.771.47
Current ratio
3.515.868.77.4412.58
Interest coverage
000-32.990
Income quality
-2.850.851.771.081.17
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.530.960.581.422.72
Research and developement to revenue
1.814.881.524.126.4
Intangibles to total assets
00000
Capex to operating cash flow
-0.010.020.030.020.01
Capex to revenue
-0.02-0.08-0.06-0.09-0.05
Capex to depreciation
-1.3-2.55-3.24-1.91-0.41
Stock based compensation to revenue
0.080.20.170.480.83
Graham number
10.99.1714.2712.9712.23
ROIC
-0.93-0.42-0.15-0.43-0.4
Return on tangible assets
-0.2-0.26-0.14-0.39-0.35
Graham Net
-4.67-3.096.873.643.67
Working capital
60.91M137.64M209.33M138.51M164.46M
Tangible asset value
-61.46M-101.05M207.88M146.97M169.76M
Net current asset value
-62.23M-103.48M196.51M134.72M156.33M
Invested capital
-1.32-2.040.030.040.06
Average receivables
00000
Average payables
01.53M2.25M2.24M2.08M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
13.6817.2718.47375.59739.3
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
26.6721.1319.760.970.49
Inventory turnover
00000
ROE
0.270.44-0.16-0.45-0.4
Capex per share
-0.02-0.02-0.06-0.04-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.150.150.050.030.01
Net income per share
-0.36-0.36-0.44-0.4-0.41
Operating cash flow per share
-0.49-0.55-0.46-0.46-0.46
Free cash flow per share
-0.49-0.55-0.46-0.46-0.46
Cash per share
4.343.844.533.67
Book value per share
4.063.723.993.583.55
Tangible book value per share
4.063.723.993.583.55
Share holders equity per share
4.063.723.993.583.55
Interest debt per share
0.180.110.130.260.22
Market cap
96.26M125.09M257.76M188.09M94.18M
Enterprise value
42.04M101.11M191.89M78.3M-14.98M
P/E ratio
-1.84-2.42-3.77-2.71-1.21
Price to sales ratio
17.6623.54128.62158.72142.91
POCF ratio
-5.45-6.32-14.21-9.41-4.32
PFCF ratio
-5.38-6.27-14.2-9.41-4.27
P/B Ratio
0.650.931.641.210.55
PTB ratio
0.650.931.641.210.55
EV to sales
7.7119.0395.7566.08-22.73
Enterprise value over EBITDA
-2.82-6.62-9.78-4.010.69
EV to operating cash flow
-2.38-5.11-10.58-3.920.69
EV to free cash flow
-2.35-5.07-10.57-3.920.68
Earnings yield
-0.14-0.1-0.07-0.09-0.21
Free cash flow yield
-0.19-0.16-0.07-0.11-0.23
Debt to equity
0.040.040.030.070.06
Debt to assets
0.030.040.030.050.06
Net debt to EBITDA
3.641.573.365.635.05
Current ratio
7.4410.1213.3810.4112.58
Interest coverage
-16.9211.97000
Income quality
1.251.391.061.151.12
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.90.992.665.0912.58
Research and developement to revenue
2.872.937.57121.2
Intangibles to total assets
00000
Capex to operating cash flow
0.010.01000.01
Capex to revenue
-0.04-0.0300-0.4
Capex to depreciation
-1.1-0.66-0.020-0.86
Stock based compensation to revenue
0.340.380.941.692.66
Graham number
5.755.466.255.675.71
ROIC
-0.09-0.1-0.1-0.11-0.12
Return on tangible assets
-0.08-0.08-0.1-0.08-0.1
Graham Net
3.643.323.623.153.2
Working capital
138.51M127.23M148.64M181.36M164.46M
Tangible asset value
146.97M135.02M156.7M155.34M169.76M
Net current asset value
134.72M123.8M145.58M140.64M156.33M
Invested capital
0.040.040.030.070.06
Average receivables
00000
Average payables
2.23M2.43M2.27M2.86M3.01M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
494.41437.17272.151.47K609.64
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.180.210.330.060.15
Inventory turnover
00000
ROE
-0.09-0.1-0.11-0.11-0.11
Capex per share
-0.01000-0.01

IKNA Frequently Asked Questions

What is Ikena Oncology, Inc. stock symbol ?

Ikena Oncology, Inc. is a US stock , located in Boston of Ma and trading under the symbol IKNA

What is Ikena Oncology, Inc. stock quote today ?

Ikena Oncology, Inc. stock price is $1.42 today.

Is Ikena Oncology, Inc. stock public?

Yes, Ikena Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap